Advances in targeting the WNT/β-catenin signaling pathway in cancer

Avradip Chatterjee, Sayan Paul, Bharti Bisht, Shelley Bhattacharya, Sudhakar Sivasubramaniam, Manash K. Paul

Research output: Contribution to journalReview articlepeer-review


WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.

Original languageEnglish (US)
Pages (from-to)82-101
Number of pages20
JournalDrug Discovery Today
Issue number1
StatePublished - Jan 2022
Externally publishedYes


  • Artificial intelligence
  • Cancer
  • Challenges
  • Clinical trials
  • Drug design
  • Inhibitors
  • Natural products
  • Nuclear transport
  • Phase transition
  • Phosphorylation
  • Protein-small molecule interaction
  • Targeting protein-protein interaction
  • WNT/β-catenin signaling

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Advances in targeting the WNT/β-catenin signaling pathway in cancer'. Together they form a unique fingerprint.

Cite this